Announcement of Metabolism and Target Organ Damage Best Paper Award 2022
We are pleased to announce the "Metabolism and Target Organ Damage Best Paper Award 2022" has been established, which aims to recognize and promote high-quality contributions to academic research. Papers (Original Articles and Review Articles) submitted to Metabolism and Target Organ Damage from May 1, 2021, to December 31, 2022, will be considered. One article will be selected for this award after a thorough evaluation by the journal's Scientific Committee and under the guidance of the whole Editorial Board team. The winner will be announced in September 2023.
"The Best Paper" will be evaluated comprehensively from following three aspects: the review report submitted by reviewers, the comprehensive evaluation by the Editorial Board team, and the number of citations (searched by Google Scholar). It should be noted that, all members of our Editorial Board will not participate in the selection of papers from the same University/institution.
We encourage authors to focus on the following factors:1. Originality of the research objectives and/or the ideas presented;
2. Creativity of the study design, or uniqueness of the approaches and concepts;
3. Scientific merit and broad impact;
4. Clarity of presentation;
5. Number of citations and downloads.
Submission date: May 1 2021 to December 31, 2022;
Publication date: before March 31, 2023;
Winner(s) announcement: by the end of September 2023.
Winner(s) will be awarded:
One First Prize: 1000 USD and an electronic certificate signed by the Editor-in-Chief;
One Second Prize: 800 USD and an electronic certificate signed by the Editor-in-Chief;
One Third Prize: 500 USD and an electronic certificate signed by the Editor-in-Chief.
All winners will be invited for a special interview to talk about their research.
All winners will have the opportunity to publish two papers free of charge in Metabolism and Target Organ Damage in 2023 after standard peer review.
All winners will be invited as the Chair or Guest Speakers to our journal webinars. The webinar will be held via Zoom and it could be broadcast live on Youtube and the Chinese WeChat Official Account, Video Account, Bilibili.
The research achievements of winners will be broadly promoted through all platforms of Metabolism and Target Organ Damage and OAE Publishing Inc.
Metabolism and Target Organ Damage (M&TOD, https://oaepublish.com/mtod, ISSN: 2769-6375) is a journal newly launched in 2021 with fast development in the past few months. It is an international, peer-reviewed, open access interdisciplinary journal which provides an online platform for the publication of clinical, basic, and translational studies. It covers (cardio)-metabolic disorders per se, such as obesity, diabetes, dyslipidemias, arterial hypertension and hyperuricemia in all age groups.
Aims and Scope: https://oaepublish.com/mtod/aims_and_scope
Published Articles: https://oaepublish.com/mtod/articles
Editorial Board team:
Amedeo Lonardo, Tutor for fellows in Internal Medicine at the University of Modena and Reggio Emilia, has been placed in the top 0.012% of scholars about "fatty liver" in the world over the past 10 years (Expertscape);
Giovanni Targher, Coordinator of the PhD program of the University of Verona Medical School, has been placed in the top 0.003% of scholars about "fatty liver" in the world over the past 10 years (Expertscape);
Christopher Byrne, Chair of Endocrinology & Metabolism at the University of Southampton, the UK expert Diabetologist advisor to the National Institute for Health and Care Excellence (NICE) NAFLD Guidelines;
Leonardo M. Fabbri, Member of the Academy of Europe, Eminent Scholar of Internal and Respiratory Medicine, Department of Morphology, Surgery and Experimental Medicine, Section of Respiratory Diseases, University of Ferrara;
Helena Cortez-Pinto, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. First female Vice President of United European Gastroenterology;
Malu Martínez-Chantar, Coordinator of the Translational Area of the National Institute for the Study of Liver and Gastrointestinal Diseases (CIBEREHD) and the Scientific Advisory Board of the Molecular Medicine Center C3M Nice and IDIVAL;
Laura E. Nagy, MERIT award from NIH and principal investigator for the Northern Ohio Alcohol Research Center. Past Chair of the Board of Scientific Counselors and current Advisory Council member for the National Institutes of Alcoholism and Alcohol Abuse;
The full list could be found via https://oaepublish.com/mtod/editor, https://oaepublish.com/mtod